Compare Albemarle Corp. (ALB) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Albemarle Corp. vs State Street SPDR S&P Biotech ETF — how do they compare? Albemarle Corp. trades at $128.35 (market cap $15.27B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: Albemarle Corp. pays a 1.27% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Albemarle Corp. nearer its low. Which is the better fit depends on your goals.
| ALB | XBI | |
|---|---|---|
Market Cap | $15.27B | — |
Sector | Basic Materials | Broad Market / Factor |
52-Week High | $215.62 | $164.28 |
52-Week Low | $72.58 | $86.92 |
Enterprise Value | $17.75B | — |
Dividend Yield | 1.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Albemarle (ALB) trades at $128.29, down 2.23% today, with mixed technical signals showing bullish moving averages but overbought RSI levels. The company reported strong Q2 2026 results with EPS of $3.75 beating estimates by 17%, driven by improved lithium pricing and specialty chemicals performance. Despite recent profitability challenges with negative net income in 2025, cash flow generation remains healthy at $1.28B from operations.
Analyst consensus leans positive with 42% buy ratings and $184.50 price target representing 44% upside potential. Key risks include lithium price volatility and Q3 margin pressure, while catalysts include sustained demand for energy storage solutions and ongoing balance sheet improvements through debt reduction.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Albemarle Corp.
Albemarle is the world's largest lithium producer. Our outlook for robust lithium demand is predicated upon increased demand for electric vehicle batteries. Albemarle produces lithium from its salt brine deposits in Chile and the U.S. and its hard rock joint venture mines in Australia. Albemarle is also a global leader in the production of bromine, used in flame retardants. The company is also a major producer of oil refining catalysts.
Read more on ALB →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
